|
Published by: Business Insights
Published: Mar. 1, 2007 - 201 Pages
Table of Contents
Executive Summary
Patient potential
Global market analysis
Pipeline analysis
Competitive landscape
Chapter 1 Patient potential
Summary
Introduction
Acne
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Psoriasis
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Infectious diseases of the skin
Overview
Bacterial infections of the skin
Fungal infections of the skin
Viral infections of the skin
Diagnosis, treatment and management
Epidemiology
Viral skin infections
Fungal skin infections
Bacterial skin infections
Forecast epidemiology
Viral skin infections
Fungal skin infections
Bacterial skin infections
Dermatitis
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Rosacea
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Licensing trends
Market analysis by drug class
Leading brands dynamics
Key events in the dermatology market
Continued approvals for biologic agents in the treatment of psoriasis
Black box warnings for Elidel and Protopic
Safety concerns over Roaccutane gain more traction
Acne treatments
Market analysis by drug class
Competitive dynamics of acne treatments
Leading acne treatment brands
Oral acne treatments market analysis
Market dynamics
Key brands analysis
Topical acne treatments market analysis
Market dynamics
Key brands analysis
Acne treatment sales forecasts to 2011
Psoriasis treatments
Market analysis by drug class
Competitive dynamics of psoriasis treatment classes
Leading brands of psoriasis treatments
Market dynamics
Key brands analysis
Psoriasis treatments sales forecasts to 2011
Corticosteroid treatments
Market analysis by drug class
Competitive dynamics of corticosteroid treatment classes
Leading brands of corticosteroid treatments
Corticosteroid treatments market analysis
Market dynamics
Key brands analysis
Corticosteroid treatment sales forecasts to 2011
Anti-infective treatments
Market analysis by drug class
Leading brands of anti-infective treatments
Market dynamics
Key brands analysis
Anti-infective treatment sales forecasts to 2011
Other dermatologic treatments
Leading brands of other dermatologic treatments
Key brands analysis
Other dermatologic treatment sales forecasts to 2011
Total Therapeutic market sales forecasts to 2011
Chapter 3 Pipeline analysis
Summary
Introduction
Key trends in R&D
New mechanism of action
Reformulations
Combination drugs
Biologics
The therapeutic area pipeline
Leading drugs in development
Profiles of key pipeline products
Phase II compounds
rambazole
Phase III compounds
Panaclar/BG-12
CNTO 1275 interleukin antagonist
Drugs in registration
Altabax (retapamulin)
Desonate (desonide)
Recently marketed drugs
Humira (adalimumab)
Oracea (doxycycline extended release sub anti-microbial dose)
Remicade (infliximab)
Taclonex (calcipotriene/betamethasone)
Ziana (clindamycin/tretinoin)
Pipeline forecasts
Factors affecting forecasts
Dermatology pipeline forecasts
Chapter 4 Competitive landscape
Summary
Introduction
Company market shares
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
GlaxoSmithKline
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Schering-Plough
Overview
Sales focus by drug class
Marketed Product Portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Sanofi-Aventis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Johnson & Johnson
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Bayer Schering Pharma
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Stiefel Labs
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Roche
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Nestle/L’Oreal
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Chapter 5 Appendix
IMS data
Index
List of Figures
Figure 1.1: Typical treatment patterns in the treatment of acne
Figure 1.2: Typical treatment patterns in the treatment of psoriasis
Figure 2.3: Global dermatology market share by geography, 2005
Figure 2.4: Sales of types of dermatology brands, 2004-5
Figure 2.5: Competitive dynamics of the global dermatology market by drug class, 2005
Figure 2.6: Competitive dynamics of the leading 10 brands in the global dermatology market,
2004-5
Figure 2.7: Competitive dynamics of subclasses in the acne treatments market, 2004-5
Figure 2.8: Competitive dynamics of the leading acne treatments in the global dermatology
market, 2004-5
Figure 2.9: Competitive dynamics of the leading oral acne treatments in the global dermatology
market, 2004-5
Figure 2.10: Competitive dynamics of the leading topical acne treatments in the global dermatology
market, 2004-5
Figure 2.11: Competitive dynamics of classes in the psoriasis treatments market, 2004-5
Figure 2.12: Competitive dynamics of the leading psoriasis treatments in the global dermatology
market, 2004-5
Figure 2.13: Competitive dynamics of classes in the corticosteroid treatments market, 2004-5
Figure 2.14: Competitive dynamics of the leading corticosteroid treatments in the global
dermatology market, 2004-5
Figure 2.15: Competitive dynamics of subclasses in the anti-infective treatments market, 2004-5
Figure 2.16: Competitive dynamics of the leading anti-infective treatments in the global
dermatology market, 2004-5
Figure 2.17: Competitive dynamics of the leading other treatments in the global dermatology
market, 2004-5
Figure 3.18: Prevailing R&D approaches, 2005
Figure 3.19: The dermatology pipeline by indication and stage of development, 2006
Figure 3.20: Leading recently launched products and late-stage R&D in the dermatology market,
2005
Figure 4.21: Competitive dynamics of the leading players in the global dermatology market, 2005
Figure 4.22: Novartis’ dermatology sales, 2005
Figure 4.23: GSK’s dermatology sales by drug class, 2005
Figure 4.24: Schering-Plough’s dermatology sales by drug class, 2005
Figure 4.25: Sanofi-Aventis’ dermatology sales by drug class, 2005
Figure 4.26: J&J’s dermatology sales by drug class, 2005
Figure 4.27: Schering AG’s dermatology sales by drug class, 2005
Figure 4.28: Stiefel Labs’ dermatology sales by drug class, 2005
Figure 4.29: Roche’s dermatology sales by drug class, 2005
Figure 4.30: L’Oreal’s dermatology sales by drug class, 2005
List of Tables
Table 1.1: Estimated prevalence of dermatological conditions in the seven major pharmaceutical
markets, 2005
Table 1.2: Estimated prevalence of clinical acne across seven major markets, 2005
Table 1.3: Forecast epidemiology of clinical acne across the seven major markets, 2005-11
Table 1.4: Estimated prevalence of psoriasis across seven major markets, 2005
Table 1.5: Forecast epidemiology of psoriasis across the seven major markets, 2005-11
Table 1.6: Estimated prevalence of infectious diseases (viral) of the skin across seven major
markets, 2005
Table 1.7: Estimated prevalence of infectious diseases (fungal) of the skin across seven major
markets, 2005
Table 1.8: Estimated prevalence of infectious diseases (bacterial) of the skin across seven major
markets, 2005
Table 1.9: Forecast epidemiology of infectious diseases (viral) of the skin across the seven major
markets, 2005-11
Table 1.10: Forecast epidemiology of infectious diseases (fungal) of the skin across the seven
major markets, 2005-11
Table 1.11: Forecast epidemiology of infectious diseases (bacterial) of the skin across the seven
major markets, 2005-11
Table 1.12: Estimated prevalence of atopic dermatitis across seven major markets, 2005
Table 1.13: Forecast epidemiology of dermatitis across the seven major markets, 2005-11
Table 1.14: Estimated prevalence of rosacea across seven major markets, 2005
Table 1.15: Forecast epidemiology of rosacea across the seven major markets, 2005-11
Table 2.16: The global dermatology market by drug class, 2001-5
Table 2.17: Leading brands in the global dermatology market, 2004-5
Table 2.18: The global acne market by drug class, 2001-5
Table 2.19: Leading acne treatments in the global dermatology market,
Table 2.20: Leading oral acne treatments in the global dermatology market, 2004-5
Table 2.21: Leading topical acne treatments in the global dermatology market, 2004-5
Table 2.22: Acne treatments sales forecast, 2005-11
Table 2.23: The global psoriasis market by drug class, 2001-5
Table 2.24: Leading psoriasis treatments in the global dermatology market, 2004-5
Table 2.25: Psoriasis treatments sales forecast, 2005-11
Table 2.26: The global corticosteroid market by drug class, 2001-5
Table 2.27: Leading corticosteroid treatments in the global dermatology market, 2004-5
Table 2.28: Corticosteroid treatment sales forecast, 2005-11
Table 2.29: The global anti-infective market by drug class, 2001-5
Table 2.30: Leading anti-infective treatments in the global dermatology market, 2004-5
Table 2.31: Anti-infective treatment sales forecast, 2005-11
Table 2.32: Leading other treatments in the global dermatology market, 2004-5
Table 2.33: Other dermatologic treatment sales forecast, 2005-11
Table 2.34: Therapeutic sales forecasts by drug class, 2005-11
Table 3.35: Dermatology pipeline forecasts, 2005-11
Table 4.36: Leading players in the global dermatology market, 2004-5
Table 4.37: Novartis’ dermatology product portfolio, 2004-5
Table 4.38: Novartis’ dermatology R&D product pipeline, 2006
Table 4.39: GSK’s dermatology product portfolio, 2004-5
Table 4.40: GSK’s dermatology R&D product pipeline, 2006
Table 4.41: Schering-Plough’s dermatology product portfolio, 2004-5
Table 4.42: Sanofi-Aventis’ dermatology product portfolio, 2004-5
Table 4.43: Johnson & Johnson’s dermatology product portfolio, 2004-5
Table 4.44: Johnson & Johnson’s dermatology R&D product pipeline, 2006
Table 4.45: Schering AG’s dermatology product portfolio, 2004-5
Table 4.46: Schering AG’s dermatology R&D product pipeline, 2006
Table 4.47: Stiefel Lab’s dermatology product portfolio, 2004-5
Table 4.48: Roche’s dermatology product portfolio, 2004-5
Table 4.49: Roche’s dermatology R&D product pipeline, 2006
Table 4.50: Nestle/L’Oreal’s dermatology product portfolio, 2004-5
Abstract
Introduction
The Dermatology Market Outlook to 2011 provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes. The in-depth 6-year epidemiology and product sales forecasts in this report will enable you to plan effectively, evaluate changes in the competitive positions of leading companies and accurately benchmark your position.
Key findings of this new report
• The psoriasis market is forecast to post the most aggressive growth rates over the period to 2011, as Raptiva and Daivobet drive growth over the forecast period. Psoriasis treatments are forecast to expand sales at a CAGR of 12.5%, reaching sales of $1.9bn in 2011.
• With Roaccutane and Diane facing generic competition, the branded oral acne treatments market is set to decline over the forecast period. Forecast sales of the acne market are estimated at $2.7bn in 2011.
• The corticosteroid market was valued at $2,783m in 2005, 5.8% up on year previous sales of $2,630m. Triple combination anti-infective/corticosteroid therapies are driving growth, whilst widespread genericization is restraining growth of the class as a whole.
The 5 Major dermatological indications covered are:
• Acne
• Psoriasis
• Infectious diseases of the skin
• Dermatitis
• Rosacea
Your questions answered
• What will be the major growth indications in the dermatology area over the period 2006-11?
• How have recent major launches from companies such as Novartis, Astellas and Genentech performed?
• Which companies will become the key players in the dermatology area over the period 2006-11?
• Which products will be impacted by generic competitors over the period 2006-11?
• What will the competitive landscape in acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infections look like in 2011?
This report will enable you to...
• Quantify patient potential, assess treatment trends and sales patterns with this report’s in-depth coverage of the 5 major dermatological indications, the US, Japanese and top EU 5 markets and the top 10 leading companies.
• Forecast sales of the major products in the dermatology area over the period 2006-11 in major dermatological indications, classes of treatments and by company.
• Evaluate how market share of leading companies, such as Novartis, GlaxoSmithKline and Schering Plough, will change over the next 6 years, and assess your competitive position within the market.
• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of dermatological treatments including corticosteroids, anti-infectives, acne treatments and psoriasis treatments.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
